JP2022521591A5 - - Google Patents
Info
- Publication number
- JP2022521591A5 JP2022521591A5 JP2021549211A JP2021549211A JP2022521591A5 JP 2022521591 A5 JP2022521591 A5 JP 2022521591A5 JP 2021549211 A JP2021549211 A JP 2021549211A JP 2021549211 A JP2021549211 A JP 2021549211A JP 2022521591 A5 JP2022521591 A5 JP 2022521591A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1902419.9 | 2019-02-22 | ||
| GBGB1902419.9A GB201902419D0 (en) | 2019-02-22 | 2019-02-22 | Treatment of kidney injury |
| PCT/EP2020/054580 WO2020169783A1 (en) | 2019-02-22 | 2020-02-21 | Treatment of kidney injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521591A JP2022521591A (ja) | 2022-04-11 |
| JP2022521591A5 true JP2022521591A5 (enExample) | 2023-02-14 |
| JP7638215B2 JP7638215B2 (ja) | 2025-03-03 |
Family
ID=65998854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549211A Active JP7638215B2 (ja) | 2019-02-22 | 2020-02-21 | 腎障害の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11339216B2 (enExample) |
| EP (1) | EP3927742A1 (enExample) |
| JP (1) | JP7638215B2 (enExample) |
| KR (1) | KR20210144708A (enExample) |
| CN (1) | CN113748131A (enExample) |
| AU (1) | AU2020224346A1 (enExample) |
| BR (1) | BR112021016613A2 (enExample) |
| CA (1) | CA3130027A1 (enExample) |
| CL (1) | CL2021002212A1 (enExample) |
| EA (1) | EA202191988A1 (enExample) |
| GB (1) | GB201902419D0 (enExample) |
| MX (1) | MX2021010025A (enExample) |
| PH (1) | PH12021552024A1 (enExample) |
| TW (1) | TWI874359B (enExample) |
| WO (1) | WO2020169783A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| TWI907583B (zh) * | 2020-12-11 | 2025-12-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | Jak抑制劑在腎臟疾病中的應用 |
| WO2023023473A1 (en) * | 2021-08-16 | 2023-02-23 | Sierra Oncology, Inc. | Methods of using momelotinib to treat chronic kidney disease |
| CN115068442A (zh) * | 2021-09-13 | 2022-09-20 | 荣灿生物医药技术(上海)有限公司 | 核酸的纳米颗粒组合物、其制备方法和用途 |
| CN113960302B (zh) * | 2021-09-29 | 2024-04-23 | 中国人民解放军军事科学院军事医学研究院 | 一种基于高内涵技术的肾毒性检测方法及其应用 |
| US20230145258A1 (en) * | 2021-11-11 | 2023-05-11 | Laboratory Corporation Of America Holdings | Predicting a Diagnostic Test Result From Patient Laboratory Testing History |
| US20250082608A1 (en) * | 2021-12-16 | 2025-03-13 | Singapore Health Services Pte Ltd. | Treatment and prevention of glomerular disease |
| CN114982708A (zh) * | 2022-05-11 | 2022-09-02 | 成都医学院第一附属医院 | 一种小鼠造影剂肾病模型及其构建方法 |
| CN119233818A (zh) | 2022-05-20 | 2024-12-31 | 学校法人藤田学园 | 用于肾损伤的治疗方法或预防方法中的药物组合物和包含该药物组合物的联用药、以及ccbl1抑制剂 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| CN120787238A (zh) | 2023-01-06 | 2025-10-14 | 拉森医疗公司 | 用于治疗甲状腺眼病的抗IL-11Rα抗体 |
| CN119925593B (zh) * | 2023-06-05 | 2025-11-25 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的药物制剂 |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| WO2025238135A2 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Antibody with binding specificity for il-11 |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| CN119548507A (zh) * | 2024-11-12 | 2025-03-04 | 安徽医科大学 | 5-甲基四氢叶酸在制备治疗肾脏纤维化的药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| MX352516B (es) | 2006-07-05 | 2017-04-06 | Fibrotech Therapeutics Pty Ltd | Compuestos terapeuticos. |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| JP5330398B2 (ja) | 2007-10-26 | 2013-10-30 | シーエスエル、リミテッド | サイトカインムテイン |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| CN117843785A (zh) | 2013-02-07 | 2024-04-09 | Csl有限公司 | Il-11r结合蛋白及其应用 |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| CN108210909A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗脂质肾损伤的药物及其用途 |
| CN108210894A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗病理性肾组织损伤的药物及其用途 |
| US20180186871A1 (en) * | 2016-12-16 | 2018-07-05 | Singapore Health Services Pte Ltd. | Il-11 antibodies |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20200031920A1 (en) | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| GB201716733D0 (en) * | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
-
2019
- 2019-02-22 GB GBGB1902419.9A patent/GB201902419D0/en not_active Ceased
-
2020
- 2020-02-21 BR BR112021016613A patent/BR112021016613A2/pt unknown
- 2020-02-21 US US16/798,101 patent/US11339216B2/en active Active
- 2020-02-21 JP JP2021549211A patent/JP7638215B2/ja active Active
- 2020-02-21 EA EA202191988A patent/EA202191988A1/ru unknown
- 2020-02-21 CA CA3130027A patent/CA3130027A1/en active Pending
- 2020-02-21 MX MX2021010025A patent/MX2021010025A/es unknown
- 2020-02-21 AU AU2020224346A patent/AU2020224346A1/en active Pending
- 2020-02-21 KR KR1020217030110A patent/KR20210144708A/ko active Pending
- 2020-02-21 CN CN202080016183.XA patent/CN113748131A/zh active Pending
- 2020-02-21 PH PH1/2021/552024A patent/PH12021552024A1/en unknown
- 2020-02-21 EP EP20707590.4A patent/EP3927742A1/en active Pending
- 2020-02-21 TW TW109105725A patent/TWI874359B/zh active
- 2020-02-21 WO PCT/EP2020/054580 patent/WO2020169783A1/en not_active Ceased
-
2021
- 2021-08-19 CL CL2021002212A patent/CL2021002212A1/es unknown
-
2022
- 2022-05-23 US US17/751,117 patent/US12234284B2/en active Active
-
2025
- 2025-01-17 US US19/028,642 patent/US20250270310A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022521591A5 (enExample) | ||
| JP2022531591A5 (enExample) | ||
| Ge et al. | Biology of interleukin-17 and its pathophysiological significance in sepsis | |
| Li et al. | The role of interleukins in colorectal cancer | |
| Roy et al. | Chemokines and chemokine receptors: update on utility and challenges for the clinician | |
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| Steeland et al. | A new venue of TNF targeting | |
| Grymula et al. | Overlapping and distinct role of CXCR7‐SDF‐1/ITAC and CXCR4‐SDF‐1 axes in regulating metastatic behavior of human rhabdomyosarcomas | |
| Jähnichen et al. | CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells | |
| JP7638215B2 (ja) | 腎障害の治療 | |
| JP2020510662A5 (enExample) | ||
| US11046773B2 (en) | Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity | |
| Villaescusa et al. | A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab | |
| US11059906B2 (en) | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| JP7514846B2 (ja) | 肝毒性の治療 | |
| JP2014509510A5 (enExample) | ||
| JP2022518251A5 (enExample) | ||
| TW200902064A (en) | Methods and compositions for modulating IL-17F/IL-17A biological activity | |
| JP2013504603A5 (enExample) | ||
| CN111542546A (zh) | 抗lag-3 抗体及其用途 | |
| JP2022539753A5 (enExample) | ||
| KR20160133479A (ko) | 자가면역 질환의 치료를 위한 조합 요법 | |
| Moreno et al. | Role of chemokines in proteinuric kidney disorders |